IGH-grade gliomas are the most frequently encountered primary malignant neoplasms in adults. 8, 28 Standard treatment for these malignant gliomas is surgery, followed by radiotherapy, chemotherapy, 6, 15, 33, 36 and even more sophisticated therapies (bioreactors, neural stem cells, immunotherapies, biodegradable polymers, convection-enhanced drug delivery, and so forth). 17 Note, however, that only malignant gliomas exhibiting LOH of chromosomes 1p and 19q are chemoresponsive. 5, 9 Unfortunately, gliomas with 1p and 19q LOH are mainly malignant oligodendrogliomas, that is, a minor proportion of malignant gliomas. 28, 42 Astrocytic tumors consist of a core mass and a penumbra of invasive single cells, decreasing in number toward the periphery and still detectable several centimeters away from the core lesion. 3, 20, 24 Cell migration consists of very complex cellular and molecular processes in which at least three independent, but highly coordinated, biological steps are involved: 1) cell adhesion to specific components of the ECM; 19, 23, 43 2) modifications in the actin cytoskeleton organization; 10,34,46 and 3) secretion of proteases. 47 Gene-expression profiling has already revealed numerous genes implicated in glioma cell migration, many of which relate to cell adhesion molecules that directly interact with specific ECM components. 32, 37, 50, 53 Gladson 22 detailed the molecular nature of ECM in gliomas and, as she emphasized, Rutka and colleagues 51, 52 were among the first to recognize the importance of the ECM in the brain and in astrocytic tumors. We have shown that interactions between oligosaccharide moieties in glioma ECM and cell adhesion molecules on the surface of glioma cells exert major effects in glioma cell migration.
As a complement to conventional chemotherapy, antiinflammatory compounds have been used successfully to combat cancer cell migration of epithelial origin (carcinoma) toward the liver. 30, 39 Metastases of epithelial cancers into the liver involve cancer cell-mediated oligosaccharide (fucose) interactions with cell adhesion molecules (selectins) present in liver microvasculatures. 30, 39, 55 Given that the levels of expression of fucose binding activities in malignant gliomas differ in relation to the levels of malignancy 12 and that these receptor types could influence the proliferation levels of human glioma cells, 13 we wondered whether adding cimetidine to temozolomide treatment could improve survival periods in immunodeficient mice bearing U373 human GBM orthotopic xenografts, compared with temozolomide treatment alone. We chose the U373 GBM for our study because the lesion has an astrocytic origin without 1p and 19q LOH and is weakly sensitive to temozolomide. 7 In addition, we showed that galectins (which are endogenous receptors for LacNAc moieties)-at least galectin-1-have major roles in glioma cell migration. 10, 11 Galectin-1 gene promoter exhibits binding sites for transcription factors activated by glucocorticoids, 21 and budesonide (an antiinflammatory agent) modifies eosinophil migration features by modifying galectin-1 expression. 16 Because we observed in the present study that cimetidine added to temozolomide improved survival in nude mice bearing U373 orthotopic xenografts, we analyzed whether cimetidine significantly modified in vitro growth compared with migration features of U373 human GBM and 9L rat gliosarcoma cells. We then determined whether cimetidine significantly modified expression levels of mannose-, fucose-, and LacNAc-related receptors in 9L rat gliosarcomas implanted orthotopically into the rat brains. We chose this 9L sarcoma for our study because of its diffuse invasive nature into the brain parenchyma. 35 
Materials and Methods
All in vivo experiments were performed with the authorization of the Animal Ethics Committee of the Faculty of Medicine of the Université Libre de Bruxelles.
Cells, Compounds, and Media
The U373 human glioma and the 9L rat gliosarcoma cells were obtained from the American Type Culture Collection (Manassas, VA). The cells were maintained as monolayers, as detailed elsewhere. 34, 35 Cimetidine was obtained from GSK (Genval, Belgium). Temozolomide was obtained from Schering-Plough (Kenilworth, NJ).
Determining In Vitro Global Growth of U373 Human GBM and 9L Rat Gliosarcoma Cells
As detailed elsewhere, 35 9L and U373 cell growth was assessed using the modified colorimetric MTT assay (Sigma, St. Louis, MO). The 9L and U373 cells were incubated for 72 hours in culture medium supplemented without (control) or with 10 
Determining In Vitro Migration Levels of U373 Human GBM and 9L Rat Gliosarcoma Cells
The 9L and U373 cell migration levels were characterized using a device that enables the trajectories of living cells maintained in culture to be quantified. 10, 11, 16, 34 The greatest linear distance migrated by each cell was calculated from these trajectories. This distance refers to the MRDO quantitative variable. 10, 11, 16, 34 All experiments were performed over 48 hours and one image was recorded every 4 minutes. A minimum of 314 and a maximum of 607 cells were analyzed in each experimental condition, as the analyses were performed in triplicate; that is, each experiment was repeated three times independently. The influence of cimetidine on 9L and U373 cell migration levels was analyzed at 10 Ϫ8 , 10
Ϫ7
, and 10 Ϫ6 M.
In Vivo Survival Analyses in Nude Mice Bearing U373 Human GBM Orthotopic Xenografts
Orthotopic xenografts of U373 human GBM cells were obtained by grafting 10 6 U373 cells into the left temporal lobes of 40 8-weekold female nu/nu mice weighing 21 to 23 g (Iffa Credo; Charles River Laboratories, L'Arbresle, France). Morphological illustrations of the in vivo growth and invasion patterns of the U373 glioma cells are featured elsewhere. 35 Four groups of 10 nude mice were established 10 days after orthotopic implantation of the tumor cells into the mice brains. The first group of 10 mice represented the control group and received nine intravenous (tail vein, three times a week for 3 consecutive weeks) and 30 intraperitoneal (five times a week for 6 consecutive weeks) injections of 0.2 ml saline, with the first injection administered on the 14th day post-tumor grafting. A second group received nine intravenous injections (same schedules as those for the control group) of 40 mg/kg temozolomide. This 40-mg/kg dose corresponds to one quarter of the maximal tolerated dose given in single intravenous administrations. 7 Twelve intravenous administrations of 40 mg/kg temozolomide represent the maximal tolerated dose of this compound when given as 12 chronic intravenous administrations (data not shown). The third group of mice received 30 intraperitoneal administrations (five times a week for 6 consecutive weeks) of 30 mg/ kg cimetidine. The fourth group received nine intravenous injections of 40 mg/kg temozolomide and 30 intraperitoneal administrations of 30 mg/kg cimetidine. Survival analyses were performed for each group.
Setting up In Vivo 9L Gliosarcomas to Characterize CimetidineInduced Effects on the Expression Levels of Endogenous Ligands for Mannose-, Fucose-, and Lactose-Related Moieties
Twenty male Fischer 344F rats (Charles River Laboratories) weighing 200 to 240 g received 40,000 9L cells by stereotactic procedures. 35 Two groups of 10 9L gliosarcoma-grafted rats were established 2 days after implantation of the tumor cells in the rat brains. The first group of rats received 15 intraperitoneal administrations of saline (control group), that is, five times a week (Monday-Friday) for 3 consecutive weeks, with the first dose delivered on the 3rd day post-tumor grafting. The second group of rats received 15 intraperitoneal doses of 30 mg/kg cimetidine. All the rats were killed (CO 2 -saturated atmosphere) on the 19th day post-tumor grafting, that is, 24 hours after the last intraperitoneal injection. We administered 15 injections only because 9L tumor-bearing rats died between the 20th and 23rd day post-tumor grafting (data not shown). The rat brains were removed and fixed in buffered formalin for 2 weeks before beginning glycohistochemical analyses.
Identification of Endogenous Receptors for Mannose-, Fucose-, and Lactose-Related Moieties
The endogenous binding sites for mannose, fucose, and lactose in 9L gliosarcomas treated with cimetidine or saline (controls) were identified in formalin-fixed, paraffin-embedded tumors by using three distinct biotinylated neoglycoconjugates, that is, BSA covalently conjugated to mannose (BSA-man), fucose (BSA-fuc), and LacNAc (BSA-LacNAc). 12 Incubation with or without (the latter for negative controls for computer-assisted microscopy) neoglycoconjugates was performed at 25 Ϯ 1˚C for 30 minutes in a 10-g/ml dilution for each probe. The extent of the specifically bound biotinylated probes was demonstrated using avidin-biotin-peroxidase complex kit reagents (Vector Labs, Burlingame, CA), with diaminobenzidine and H 2 O 2 as the chromogenic substrates. Two control experiments were performed for each of the three marker substances: 1) the omission of the incubation step with the specific neoglycoprotein to be analyzed; and 2) the incubation of the labeled probe in the presence of a 200-fold excess amount of the corresponding mono-or disaccharide. These control reactions enabled sugar specificity to be ascertained for each carrier-immobilized oligosaccharide, as described previously. 12 Omission of the incubation step with a labeled marker served to exclude any staining by the binding of kit reagents such as the mannose-rich glycoprotein horseradish peroxidase and avidin. Counterstaining with hematoxylin concluded the processing.
Computer-assisted microscopy was used to determine quantitatively the expression levels of endogenous ligands for the mannose-, fucose-, and LacNAc-related oligosaccharide moieties. Two variables were computed for each of the three biotinylated neoglycoconjugate-related stainings by using a computer-assisted microscope system (SAMBA 2005; UNILOG, Grenoble, France) with a 20ϫ (aperture 0.50) magnification lens. The labeling index refers to the percentage of tissue area specifically stained by a histochemical probe. The mean optical density denotes the staining intensity. The way in which we used the computer-assisted system to quantify the histochemical staining has been detailed previously. 11, 12 The software used on the computer-assisted microscope automatically subtracted the labeling index and mean optical density values of the negative control sample from each corresponding positive one. Special software programs were run on the computer assisting the microscope to check any inherent shading, glare, and the level of linearity precision in the CCD camera-based systems. Shading and glare were checked every week. The monitoring program installed on the computer-assisted microscope showed that shading, glare, or linearity did not significantly modify our results (data not shown). All slides relating to a given histochemical probe were stained together to minimize reproducibility problems.
After processing with each of the three glycohistochemical markers, 20 areas of between 60,000 and 120,000 m 2 were scanned on each of the four histological slides for each of the 20 9L gliosarcomas under study. A computer mouse linked to the software on the computer-assisted microscope enabled analysis of the invading islets of tumor cells separately from the tumor core.
Statisical Analysis
Statistical comparisons of the different groups were made by first performing the Kruskal-Wallis test (a nonparametric one-way analysis of variance). When this test revealed some significant differences, we compared pairs of groups by applying the Dunn procedure (twosided test) for multiple comparisons. The rank correlation test involved the nonparametric Kendall test. All statistical analyses were performed using Statistica (Statsoft, Tulsa, OK). A value less than 0.05 was defined as statistically significant.
Results

Effects of Combined Temozolomide and Cimetidine on Survival in Nude Mice Bearing U373 Human GBM Orthotopic Xenografts
The weights of the U373 xenograft-bearing nude mice were recorded to monitor potential toxic side effects of the various treatments applied in the present study. The three treatments-temozolomide alone, cimetidine alone, and the combination of temozolomide and cimetidine-were well tolerated by the U373 xenograft-bearing mice as they did not lose significant weight compared with the control animals (data not shown). Cimetidine or temozolomide alone induced no statistically significant increase in survival (Fig.  1) . In contrast, the combined treatment of temozolomide and cimetidine significantly increased survival. Indeed, five of the nine U373 GBM-bearing mice that benefited from this combined treatment died after the last control mouse.
In Vitro Cimetidine-Mediated Effects on the Global Growth Pattern of 9L Rat Gliosarcoma and U373 Human GBM Cell Lines
We determined whether the survival benefit added by cimetidine in the combined treatment (cimetidine and temozolomide) of U373 xenograft-bearing nude mice (Fig. 1 ) could relate to a cimetidine-induced decrease in the global growth rates of the GBM cells. Results of in vitro colorimetric MTT-based assays revealed that cimetidine significantly decreased the growth rates of both U373 GBM and 9L gliosarcoma cells at concentrations equal to, or higher than, 100 M (data not shown). These concentrations were not compatible with the effects observed in vivo, which occurred at significantly lower doses. Thus, we investigated whether cimetidine was able to modify the migration levels of both U373 and 9L tumor cells, as detailed later. Figure 2A illustrates the migration pattern of U373 human GBM cells during a 24-hour observation period. One image was digitized every 4 minutes during this 24-hour period, and a sequence of 360 digitized images was compiled into a movie that lasted up to 20 seconds. The software that we developed allowed us to digitize each cell, and thereafter the digitized image of the cell was reduced to its center of gravity. The centers of gravity of each cell that had been recorded every 4 minutes for a maximum of 24 hours were then linked together, each color line in Fig. 2B indicating the trajectory followed by each U373 cell. Data revealed that certain cells traveled rather linearly in the CCD camera-related field of observation, whereas others moved at random near their initial position. We recorded the MRDO (quantitative variable expressed in micrometers/hour) to characterize the migration level of each cell (Fig. 2C) . Giv- 2 . Characterization of the influence of cimetidine on the migration levels of U373 human GBM and 9L rat gliosarcoma cells. A: A computer-assisted phase-contrast microscopy image demonstrating the migration pattern of a U373 GBM cell population. One image was obtained every 4 minutes during a period of 24 hours. Original magnification ϫ 100. B: Image obtained using software we developed, demonstrating the distance traveled by each individual cell during a 24-hour observation period. C: Illustration depicting representative tumor cells (black oval) reduced to their center of gravity. All centers of gravity for a given cell were recorded during a 24-hour period and linked together to show the cell's trajectory. Tumor cell c1 did not migrate; that is, the beginning (b1) of its trajectory was nearly superposed on the end (e1) of its trajectory. In contrast, cell c2 did migrate; the beginning (b2) of its trajectory was far away from the end en that our data ( Fig. 2A-C) clearly indicated that in vitro tumor cell populations-at least the U373 human GBM and 9L rat gliosarcoma cell lines (data not shown)-exhibit dramatically pronounced features of cell heterogeneity when cell proliferation and cell migration are considered together, we analyzed the influence of cimetidine on migrating cells. Therefore, on the one hand, we determined the effects of cimetidine on the entire population of U373 and 9L cells, that is, 100% of the cells that were tracked using the CCD camera ( Fig. 2E and G) ; these tumor cell populations included proliferating as well as migrating cells ( Fig. 2A and  B) . On the other hand, we analyzed pure migrating tumor cell populations, that is, 25% of the most motile tumor cells (Fig. 2D) among the entire tumor cell population analyzed ( Fig. 2F and H) .
In Vitro Cimetidine-Mediated Effects on the Migration Levels of 9L Rat Gliosarcoma and U373 Human GBM Cell Lines
The levels of U373 GBM ( Fig. 2E and F) and 9L gliosarcoma ( Fig. 2G and H) cell migration in control conditions-that is, the cells not treated with cimetidine-were arbitrarily normalized at 0% of the MRDO values. The horizontal rectangle (p Ͼ 0.05) in each graph in Fig. 2E to H indicates that modifications between Ϫ10 and 10% of the MRDO values approximating the 0% control value are not statistically significant. Modifications of MRDO values between Ϫ10 and Ϫ20% compared with the 0% control value are weak but statistically significant (p Ͻ 0.05). The modifications in MRDO values below Ϫ20% compared with the 0% control value are statistically significant (p Ͻ 0.01).
The addition of 10 nM cimetidine did not significantly modify migration levels of GBM and gliosarcoma cells (Fig. 2E and G, respectively) , compared with the control condition. In contrast, 100 and 1000 nM cimetidine significantly decreased the migration levels of both GBM and gliosarcoma cells 36 hours after adding the agent to the culture medium. These effects were much more marked in 25% of the most motile (Fig. 2D) GBM (Fig. 2F ) and gliosarcoma (Fig. 2H ) cell subpopulations.
Influence of Cimetidine on Glycohistochemical Expression Levels of Mannose-, Fucose-, and LacNAc-Specified Endogenous Receptors in 9L Gliosarcoma Cells Grown In Vivo in Rat Brains
We separately analyzed the expression levels of endogenous mannose-, fucose-, and LacNAc-related receptors, exposing neoglycoproteins in the core (C in Fig. 3A ) of gliosarcomas as opposed to islets (II in Fig. 3A ) of 9L cells invading the brain parenchyma. Note that the 9L gliosarcoma is highly invasive through the brain parenchyma; it exhibits high proliferation indices and is well vascularized (Fig. 3B) . Given that we observed no statistically distinct expression levels of the binding sites for the three glycohistochemical markers in these two histological compartments (data not shown), we pooled the data together for the sake of clarity (Fig. 3C and D) .
Cimetidine did not significantly modify the percentage of 9L tumor cells exhibiting endogenous ligands for mannoserelated oligosaccharide moieties (Fig. 3C) , whereas it weakly, but significantly, decreased the concentration of endogenous ligands for mannose-related oligosaccharide moieties in 9L tumor cells (Fig. 3D) . Figure 3E illustrates the glycohistochemical pattern of mannose-specific endogenous receptors in a control 9L gliosarcoma.
Cimetidine markedly decreased the percentage of 9L tumor cells exhibiting endogenous receptors for fucose moieties (Fig. 3C) ; it also significantly decreased the concentration of endogenous receptors for fucose moieties in 9L tumor cells (Fig. 3D) . Figure 3G and H illustrate the glycohistochemical pattern of receptors for fucose in a control and in a cimetidine-treated 9L gliosarcoma, respectively.
Cimetidine weakly, but significantly, decreased the percentage of 9L tumor cells exhibiting endogenous receptors for LacNAc moieties (Fig. 3C) , whereas it did not significantly modify the density of endogenous receptors for LacNAc moieties in 9L tumor cells (Fig. 3D) . Figure 3F illustrates the glycohistochemical pattern of LacNAc-specific endogenous receptors in a control 9L gliosarcoma.
Discussion
Malignant gliomas are biologically heterogeneous and include subpopulations of proliferating and migrating cells. 17, 20, 28 Although certain intracellular signaling pathways specifically control cell proliferation and/or apoptosis, other intracellular signaling pathways control cell migration. 3, 20, 29, 45 For example, CAS/Crk assembly serves as a molecular switch for the induction of cell migration and appears to contribute to the invasive property of tumors. 29 Because of the presence of distinct subpopulations of proliferating and migrating cells in malignant gliomas, adjuvant chemotherapy currently used to combat proliferating glioma cells is weakly, if at all, effective against migrating glioma cells. There is also accumulating evidence that invasive glioma cells show a decreased proliferation rate and a relative resistance to apoptosis, which may contribute to chemotherapy and radiotherapy resistance. 8, 20, 29, 45 Therefore, it should be interesting to elaborate new therapeutic strategies aiming to combat migrating glioma cells. One major target in the fight against glioma cell migration relates to the successful decrease in protease expression by glioma cells. 47 Another major target concerns adhesion molecules and their ligands in the ECM. By example, tenascin, an integrin ligand, is overexpressed in the ECM of malignant gliomas compared with its expression in low-grade gliomas or normal brain parenchyma, 22 and clinical applications are undertaken specifically to combat this particular feature of glioma cell migration. 48 Apart from integrins, 22, 26, 44 galectins 10-12 also exert crucial roles in glioma cell migration. Whereas integrins use protein-protein interactions with ECM components, galectins use protein-carbohydrate interactions between themselves and ECM glycoproteins. Note that the core of carbohydrate ligands for galectins are represented by LacNAc moieties. With respect to the metastatic process of epithelial cells colonizing the liver, the interactions between a third group of adhesion molecules, that is, selectins, and their fucosylrelated LacNAc ligands (Lewis antigens) also play crucial roles. 27, 39, 55 In fact, epithelial cells detaching from primary epithelial tumors (carcinomas) and migrating through the lymphatic system or the blood vessels eventually colonize the liver given the fact that cancerous epithelial cells exhibiting Lewis antigens on their surface are able to adhere to endothelial cells in liver sinusoids, because of the presence of selectins (the ligands for Lewis antigens) in these liver endothelial cells. 25, 27, 39, 55 On entry in the hepatic circulation, epithelial tumor cells can rapidly trigger a molecular cascade (involving interleukin-1 secretion by tumor cells), leading to the induction of E-selectin expression on the sinusoidal endothelium. 25, 27 Cimetidine is a histamine receptor-type H2 blocker and its use in clinics has already been proven to be beneficial in patients with colon cancer 30, 39 because it antagonizes tumor cell-mediated interleukin-1-induced activation of selectins in liver sinusoids, 30, 39 therefore reducing the binding capacities of tumor cells on liver sinusoids. Furthermore, in some cases, histamine is able to act as a growth factor through the activation of H2 receptors, 18 and cimetidine has already been shown to be capable of reducing in vitro or in vivo growth rates of a large panel of human cancers, including nontumorous cells of colon origin 1 as well as melanomas 49 and gliomas. 18 In the present study, we showed that cimetidine-mediated effects on U373 human GBM and 9L rat gliosarcoma cell growth occurred at concentrations of approximately 100 M, whereas such effects on migration levels of these tumor cells occurred at approximately or below M ranges of doses. Thus, the in vivo benefit demonstrated by the addition of cimetidine to temozolomide with respect to the survival periods in mice bearing U373 human GBM orthotopic xenografts, compared with temozolomide alone (Fig. 1) , refers to decreases in cell migration capacities rather than in cell growing capacities. We observed in vitro that cimetidine induced no modification in either cell cycle kinetics or apoptotic features with the use of doses between 100 and 0.1 M (data not shown).
The CD15 epitope (fucosyl-LacNAc) is present on almost all types of carcinoma cells (gastric, pancreatic, colon, breast, and so forth) and even on normal astrocytes, whereas it is absent on glioma cells. 38 Martin and colleagues 38 asserted that the absence of CD15 on human glioma cells may explain, to some extent, the general failure of intrinsic brain gliomas to metastasize by precluding the adhesion of circulating glioma cells to target organ endothelium. Although CD15 is absent from glioma cells, other fucosyl-related oligosaccharide moieties have very important roles in glioma cell biology. Indeed, fucose-containing glycoproteins have been suspected as candidates for the tumor suppressor function in GBM cells. 54 Berezovskaya, et al., 4 observed an upregulation of fucose residues on the cell membranes of C6 glioma cells when the tumor cells were submitted to starvation, that is, a dramatic decrease in serum concentration. We monitored the expression of glycan-binding sites on a panel of 10 biotinylated neoglycoconjugates in 108 human astrocytic tumors, and clear differences were observed between nondiffuse (pilocytic) and diffuse (astrocytic) tumors, including distinct levels of fucose-related oligosaccharide moieties. 12 Analysis of data from the present study showed that cimetidine markedly decreased both the percentage of 9L rat gliosarcoma cells with endogenous receptors for fucose moieties and the 9L tumor cell density for such receptors. We observed similar features with the U373 cells in a preliminary experiment (data not shown). This cimetidine-mediated decrease in endogenous receptors for fucose moieties could, at least partially, explain the cimetidine-induced decrease in 9L (and U373) tumor cell migration and the in vivo benefit of adding cimetidine to temozolomide (Fig. 1) .
Fucose-containing glycans with potential clinical applications are hypothesized to combat the development of malignant gliomas. Indeed, it has been known for a long time that the astrocyte number is constant in the mammalian central nervous system during adulthood and old age in normal circumstances because of the balance of division promoters and division inhibitors. 31 Nieto-Sampedro 40 identified the mitogen inhibitors as immunologically related to blood group oligosaccharides (that is, Lewis antigen-related structures) and to glycan epitopes of the epidermal growth factor receptor. On the basis of these data, Aguilera, et al., 2 synthesized a family of oligosaccharides with a common Lewis X-type structure (that is, fucosyl-LacNAc-related structures), and these compounds exerted significant antiproliferative activity against malignant GBM cells. 41 Data in the present study also revealed that cimetidine slightly, but significantly, decreases the expression levels of endogenous receptors for LacNAc moieties. Such endogenous ligands definitely involve distinct types of galectins including, for example, galectin-1, whose expression levels can be modulated by antiinflammatory compounds. 14, 16, 21 We clearly demonstrated the role played by galectin-1 on glioma cell migration features. 10, 11 Thus, the cimetidine-induced decrease in endogenous ligands for LacNAc (maybe galectin-1) can synergistically act with the cimetidine-induced decrease in endogenous receptors for fucose on both 9L and U373 tumor cell migration levels (Fig. 2) and, in turn, on the in vivo benefit contributed by adding cimetidine to temozolomide (Fig. 1) . We observed that Medrol induced no effect on galectin expression in U373 and 9L tumors (data not shown).
Conclusions
In summary, analysis of data in the present study showed that adding cimetidine, an antiinflammatory agent acting as a histamine H2 receptor antagonist, to temozolomide contributes a survival benefit compared with the use of temozolomide alone in nude mice bearing U373 human GBM orthotopic xenografts. This beneficial effect could relate to a cimetidine-induced decrease in GBM cell migration capacities, a decrease probably linked to cimetidine-induced modifications in the expression levels of endogenous receptors for fucosyl-and LacNAc-containing oligosaccharide moieties.
